Measure Abbreviation: PONV 01 (MIPS 430)

Similar documents
Measure Abbreviation: PONV 01 (MIPS 430)

NQS Domain: Patient Safety. Measure Type: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority

Measure Summary: The opioid equivalency measure examines opioid administration for patients who undergo a surgical procedure.

Gastrointestinal and urinary complications in the postoperative period

Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories

Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem

Satisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone

Postoperative Nausea and Vomiting: Update on Prevention, Rescue, and Novel Strategies

Low-dose Granisetron for the Prevention of Postoperative Nausea and Vomiting

problems with, 29, 98 psychiatric patients, 96 rheumatic conditions, 97

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists

4/18/2018. Disclosure. Learning Objectives. St. Vincent Healthcare. Supportive Literature. Background

2018 Perioperative Management of PDNV

General anesthetics. Dr. Shamil AL-Noaimy Lecturer of Pharmacology Dept. of Pharmacology College of Medicine

DEXAMETHASONE WITH EITHER GRANISETRON OR ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC SURGERY

Pharmacologic Options Peripartum Analgesia Day 3. Inhalational agents Sedatives Anti-emetics Reversal Agents Postpartum Analgesia

Temperature Monitoring Locations: For TEMP 01, any temperature measurement coming from a physiologic monitor will suffice (peripheral or core).

Editor s key points. M. S. Green*, P. Green, S. N. Malayaman, M. Hepler, L. J. Neubert and J. C. Horrow

Palonosetron vs Ondansetron for prevention of postoperative nausea and vomiting in...

Dexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy

ERAS: Enhanced Recovery After Surgery. Christopher L. Wu, M.D. Professor of Anesthesiology The Johns Hopkins University; Baltimore, Maryland

Dexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery

Drugs for Local and General Anesthesia. Copyright 2017, 2014, 2011 Pearson Education, Inc. All Rights Reserved

New Drugs in Pediatric Anesthesia

Anesthetic Techniques in Endoscopic Sinus and Skull Base Surgery

Nausea and vomiting after surgery

Clinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid

A Comparative Clinical Study Of Prevention Of PostOperative Nausea And Vomiting Using Granisetron And

(30689) PROT Pain PCA Adult Patient Controlled Analgesia

Adult Care Plan Allergies: Date / / OR. Anesthesia Technique. Airway Mal / SMS FB / TMJ / CS / Teeth. Induction Agents

ANESTHESIA DRUG REVIEW

See Important Reminder at the end of this policy for important regulatory and legal information.

Chapter 25. General Anesthetics

Antiemetic Prophylaxis for Office-based Surgery

Nerve Blocks & Long Acting Analgesia for Plastic Surgeons. Karol A Gutowski, MD, FACS

Remifentanil. Addressing the challenges of ambulatory orthopedic procedures 1-3

Table of Contents. Equipment & Technology. General. Obstetric Anesthesia. Regional Anesthesia

Efficacy of a single-dose ondansetron for preventing post-operative nausea and vomiting

PONV : The big little problem. Dr.Dewinter

Cigna Drug and Biologic Coverage Policy

Dhawal R. Wadaskar*, Jyoti S. Magar, Bharati A. Tendolkar

Postoperative nausea and vomiting prophylaxis: The efficacy of a novel antiemetic drug (palonosetron) combined with dexamethasone

Screening - inclusion criteria

Original Article Antiemetics in Prolong Surgeries Pak Armed Forces Med J 2015; 65(3):353-57

The Association of Paediatric Anaesthetists of Great Britain & Ireland. Guidelines on the Prevention of Post-operative Vomiting in Children

Clinical Research INTRODUCTION. Gwieun Yeo 1, Mi Kyoung Lee 1, Heezoo Kim 1, Myounghoon Kong 1, Hyo Jung Son 2, and Han Byeol Oh 2

GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi

Dexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery

Neurokinin-1 Receptor Antagonists in Preventing Postoperative Nausea and Vomiting

Screening - inclusion criteria

Comparison of Drugs and Intravenous Crystalloid in Reduction of Postoperative Nausea and Vomiting after Laparoscopic Surgery

Managing Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting

Anesthesia for OutPatient Spine Surgery. Michael A. Kellams, D.O.

PAAQS Reference Guide

Reexamining Metoclopramide s Role in the Prevention of Postoperative Nausea and Vomiting: A Secondary Analysis

SEEING KETAMINE IN A NEW LIGHT

WORRIED ABOUT PAIN AFTER ORAL SURGERY?

Regulatory Status FDA-approved indications: Emend is a substance P/neurokinin 1 (NK1) receptor antagonist, indicated: (1-2)

DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***

LOW DOSE INTRAVENOUS MIDAZOLAM FOR PREVENTION OF PONV, IN LOWER ABDOMINAL SURGERY

Help Prevent Medication Errors with PDC Healthcare s Anesthesia Labels & Tapes

Senior Visceral Surgery Fast-Track in Colorectal Surgery The anesthetist s point of view

Incidence of and risk factors for postoperative nausea and vomiting at a Japanese Cancer Center: first large-scale study in Japan

Management of post-strabismus nausea and vomiting in children using ondansetron: a value-based comparison of outcomes 1^

Opioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting in bariatric surgery beyond triple prophylaxis

General Anesthesia. Mohamed A. Yaseen

Is lorazepam effective at preventing nausea and vomiting after laparoscopic cholecystectomy? A randomized controlled trial

Ondansetron and Extrapyramidal Effects. Rachel Lengle DNP, CRNA

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

ASSESSMENT OF THE PAEDIATRIC NEEDS ANAESTHESIOLOGY DISCLAIMER

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients

Setting The setting was secondary care. The economic study was carried out in the USA.

JMSCR Vol 07 Issue 04 Page April 2019

Appendix A: Pharmacologic approaches to pain management during MVA

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

Drug Class Review on Newer Antiemetics

J. Basic. Appl. Sci. Res., 2(9) , , TextRoad Publication

J Med Assoc Thai 2016; 99 (5): Full text. e-journal:

Opioid Free Anesthesia

Reply to the Joint Editors-in-Chief Request for Determination Regarding Papers Published by Dr. Yoshitaka Fujii, dated April 9, 2012

WHS POSTOPERATIVE POWERPLAN CHANGES

PONV and The Role of Therapeutic Decision Support

ISPUB.COM. A Wadaskar, N Swarnkar, A Yadav INTRODUCTION METHODS

Evaluation of Postoperative Complications Occurring in Patients after Desflurane or Sevoflurane in Outpatient Anaesthesia: A Comparative Study

Clinical Study Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Patients

The management of acute surgical pain has

CONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY?

Breast Augmentation: Reducing Postoperative Nausea and Vomiting. A Prospective Study

May 2013 Anesthetics SLOs Page 1 of 5

Evaluation of Three 5-HT 3

To staple or to sew. Zeng Xuan Hu

The Comparison Effect of Preoperative Ondansetron and Metoclopramide in Reducing Nausea and Vomitting after Loparoscopic Cholecystectomy

Antiemetic in Caesarean section under spinal anaesthesia: new option

Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial

PRINCIPLES OF SMALL ANIMAL ANESTHESIA & PERIOPERATIVE ANALGESIA Obiettivo n 24 - Sanità veterinaria. MODULE 1: May 8, 2014

TRIALS. Sergio Bergese 1*, Adolfo Viloria 1, Alberto Uribe 1, Alejandra Antor 1 and Soledad Fernandez 2

Index. Enhanced Recovery in NSQIP (ERIN), 240 Epidural analgesia, 149 Epidural-induced hypotension (EIH) management, ERAS

post-operative, nausea, vomiting, antiemetics

Transcription:

Measure Abbreviation: PONV 01 (MIPS 430) *PONV 01 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination Therapy measure. MIPS measure specifications are available for download at https://qpp.cms.gov/resources/education Description: Percentage of patients, aged 18 years and older, who undergo a procedure under an inhalational general anesthetic, AND who have three or more risk factors for post-operative nausea and vomiting (PONV), who receive combination therapy consisting of at least two prophylactic pharmacologic antiemetic agents of different classes preoperatively or intraoperatively. NQS Domain: Patient Safety Measure Type: Process Scope: Measured on a per case basis Measure Summary: The PONV 01 (MIPS 430) measure identifies the percentage of adult patients who undergo a surgical procedure under an inhalational general anesthetic, and who have three or more risk factors for postoperative nausea and vomiting (PONV), who receive combination therapy consisting of at least two prophylactic pharmacologic antiemetic agents of different classes preoperatively or intraoperatively. The purpose of this process of care measure is to reduce the incidence of postoperative nausea and vomiting in adult surgical patients. Rationale (Directly quoted from MIPS 430): Postoperative nausea and vomiting (PONV) is an important patient-centered outcome of anesthesia care. PONV is highly dis-satisfying to patients, although rarely life-threatening. A large body of scientific literature has defined risk factors for PONV; demonstrated effective prophylactic regimes based on these risk factors, and demonstrated high variability in this outcome across individual centers and providers. Further, a number of papers have shown that performance can be assessed at the level of individual providers- the outcome is common enough that sufficient power exists to assess variability and improvement at this level. 1,2 Inclusions: All patients, aged 18 years and older, who undergo any procedure including surgical, therapeutic, or diagnostic under an inhalational general anesthetic, AND who have three or more risk factors for PONV. o PONV Risk Factors: Female gender History of PONV History of motion sickness n-smoker Intended administration of opioids for post-operative analgesia. This includes use of opioids given intraoperatively and whose effects extend into the post

(PONV 01-MIPS 430) Measure Specification Page 2 of 10 anesthesia care unit (PACU) or post-operative period, or opioids given in the PACU, or opioids given after discharge from the PACU. Procedures (by CPT) included: 00100, 00102, 00103, 00104, 00120, 00124, 00126, 00140, 00142, 00144, 00145, 00147, 00148, 00160, 00162, 00164, 00170, 00172, 00174, 00176, 00190, 00192, 00210, 00211, 00212, 00214, 00215, 00216, 00218, 00220, 00222, 00300, 00320, 00322, 00326, 00350, 00352, 00400, 00402, 00404, 00406, 00410, 00450, 00454, 00470, 00472, 00474, 00500, 00520, 00522, 00524, 00528, 00529, 00530, 00532, 00534, 00537, 00539, 00540, 00541, 00542, 00546, 00548, 00550, 00560, 00566, 00580, 00600, 00604, 00620, 00625, 00626, 00630, 00632, 00635, 00640, 00670, 00700, 00702, 00730, 00740, 00750, 00752, 00754, 00756, 00770, 00790, 00792, 00794, 00796, 00797, 00800, 00802, 00810, 00820, 00830, 00832, 00834, 00836, 00840, 00842, 00844, 00846, 00848, 00851, 00860, 00862, 00864, 00865, 00866, 00868, 00870, 00872, 00873, 00880, 00882, 00902, 00904, 00906, 00908, 00910, 00912, 00914, 00916, 00918, 00920, 00921, 00922, 00924, 00926, 00928, 00930, 00932, 00934, 00936, 00938, 00940, 00942, 00944, 00948, 00950, 00952, 01112, 01120, 01130, 01140, 01150, 01160, 01170, 01173, 01180, 01190, 01200, 01202, 01210, 01212, 01214, 01215, 01220, 01230, 01232, 01234, 01250, 01260, 01270, 01272, 01274, 01320, 01340, 01360, 01380, 01382, 01390, 01392, 01400, 01402, 01404, 01420, 01430, 01432, 01440, 01442, 01444, 01462, 01464, 01470, 01472, 01474, 01480, 01482, 01484, 01486, 01490, 01500, 01502, 01520, 01522, 01610, 01620, 01622, 01630, 01634, 01636, 01638, 01650, 01652, 01654, 01656, 01670, 01680, 01682, 01710, 01712, 01714, 01716, 01730, 01732, 01740, 01742, 01744, 01756, 01758, 01760, 01770, 01772, 01780, 01782, 01810, 01820, 01829, 01830, 01832, 01840, 01842, 01844, 01850, 01852, 01860, 01924, 01925, 01926, 01930, 01931, 01932, 01933, 01935, 01936, 01951, 01952, 01961, 01962, 01963, 01965, 01966 Exclusions: Patients <18 years old. Procedures (by CPT): 00452, 00561, 00562, 00563, 00567, 00622, 00634, 01916, 01920, 01922, 01953, 01958, 01960, 01968, 01969, 01990, 01991, 01992, 01996, 01999 Labor Epidurals (CPT: 01967) Obstetric n-operative Procedure Rooms (Rooms tagged as OB-GYN Labor and Delivery) Obstetric n-operative Procedures with procedure text: Labor Epidural

(PONV 01-MIPS 430) Measure Specification Page 3 of 10 MPOG Concept IDs Required: General Inhalational Anesthetic MPOG Concept IDs 3297 Enflurane Exp % 3298 Enflurane Insp % 3006 Isoflurane actual consumption (ml) 3007 Desflurane actual consumption (ml) 3260 Isoflurane Exp % 3265 Isoflurane Insp% 3280 Desflurane Exp % 3285 Desflurane Insp % 50420 Cardiopulmonary bypass Isoflurane vaporizer turned on 3008 Sevoflurane actual consumption (ml) 3270 Sevoflurane Exp % 3275 Sevoflurane Insp % 3503 Sevoflurane (mmhg) 3250 Nitrous Insp % 3255 Nitrous Exp % Antiemetic MPOG Concept IDs (by class) 10335 Ondansetron 10164 Dolasetron 10208 Granisetron 10400 Scopalamine Patch 10399 Scopaloamine 11040 Butylscopolamine Class: 5-Hydroxytryptamine (5-HT3) Receptor Antagonists Anticholinergics

(PONV 01-MIPS 430) Measure Specification Page 4 of 10 Antiemetic MPOG Concept IDs (by class)- Continued Antihistamines 10257 Dimenhydrinate 10160 Diphenhydramine 10169 Droperidol 10210 Haloperidol 10035 Aprepitant 10179 Fosaprepitant 10374 Promethazine 10373 Prochlorperazine 10147 Dexamethasone Butyrophenones Neurokinin-1 Receptor Agonists Phenothiazines Steroids PONV Medical Reason Exclusion MPOG Concept ID 50046 Medical Performance Exclusion- PONV PONV Risk Factor- Smoking Status MPOG Concept IDs: 70128 History- Social History- Tobacco 71100 History- Social History- Tobacco Details Pack Years 71110 History- Social History- Tobacco details Current vs Past PONV Risk Factor- History of PONV/Motion Sickness MPOG Concept IDs: 70225 Assessment and Plan - Comments 70302 Assessment and Plan- Anesthetic Consideration 70338 General- PONV Risk Factors

(PONV 01-MIPS 430) Measure Specification Page 5 of 10 70339 General- PONV Risk Total Score 70080 General- Previous Anesthetic Problem 70102 Misc- Motion Sickness PONV Risk Factor- Intended Administration of Opioids for Postop Analgesia MPOG Concept IDs: 70234 Assessment and Plan Postop Pain Management 10008 Bupivacaine w/ Hydromorphone 0.1% / Unspecified 10020 Alfentanil 10077 Bupivacaine w/ Fentanyl 0.0625% / 3 mcg/ml 10079 Bupivacaine w/ Fentanyl 0.08% / 2 mcg/ml 10080 Bupivacaine w/ Fentanyl 0.125% / 2 mcg/ml 10081 Bupivacaine w/ Fentanyl 0.125% / 3 mcg/ml 10082 Bupivacaine w/ Hydromorphone 0.0625% / 5 mcg/ml 10083 Bupivacaine w/ Hydromorphone 0.0625% / 10 mcg/ml 10103 Bupivacaine w/ Fentanyl 0.125% / 5 mcg/ml 10186 Fentanyl 10187 Fentanyl / Midazolam 40mcg/mL / 200mcg/mL 10219 Hydromorphone 10258 Bupivacaine w/ Hydromorphone 0.05% / 3 mcg/ml 10279 Meperidine 10290 Methadone 10306 Morphine 10341 Oxycodone 10408 Bupivacaine w/ Fentanyl 0.0625% / 5 mcg/ml 10414 Sufentanil

(PONV 01-MIPS 430) Measure Specification Page 6 of 10 PONV Risk Factor- Intended Administration of Opioids for Postop Analgesia MPOG Concept IDs: 10439 Bupivacaine w/ Sufentanil w/ Epinephrine 100 mg / 100 mcg / 0.42 mg 10475 Bupivacaine w/ Hydromorphone 0.125% / 5 mcg/ml 10476 Bupivacaine w/ Hydromorphone 0.125% / 10 mcg/ml 10478 Lidocaine w/ Hydromorphone 2% / 10 mcg/ml 10479 Lidocaine w/ Fentanyl w/ Epinephrine w/ Bicarbonate 2% / 5 mcg/ml / 1:200,000 10481 Oxycodone / Acetaminophen 5 mg / 325 mg 10482 Hydrocodone / Acetaminophen 5 mg / 325 mg 10483 Hydrocodone / Acetaminophen 7.5 mg / 500 mg 10486 Bupivacaine w/ Fentanyl 0.5% / 3 mcg/ml 10488 Bupivacaine w/ Fentanyl 0.5% / 10 mcg/ml 10518 Bupivacaine w/ Hydromorphone 0.5% / 10 mcg/ml 10519 Bupivacaine w/ Fentanyl 0.05% / 3 mcg/ml 10522 Bupivacaine w/ Morphine 0.75% / 0.2 mg 10534 Bupivacaine w/ Fentanyl 0.0625% / 2 mcg/ml 10536 Bupivacaine w/ Fentanyl 0.0625% / 10 mcg/ml 10554 Bupivacaine w/ Fentanyl 0.1% / 2 mcg/ml 10583 Bupivacaine w/ Fentanyl 0.0625% / 4 mcg/ml 10584 Bupivacaine w/ Fentanyl 0.0625% / 10 mcg/ml 10585 Bupivacaine w/ Fentanyl 0.125% / 4 mcg/ml 10597 Propofol w/ Alfentanil 10 mg/ml + 50 mcg/ml 10603 Bupivacaine w/ Hydromorphone 0.05% / 10 mcg/ml 10611 Bupivacaine w/ Fentanyl w/ Epinephrine 37.5 mg / 750 mcg / 0.125 mg 10620 Bupivacaine w/ Fentanyl 0.125% / 10 mcg/ml 10633 Ropivacaine w/ Fentanyl 0.125% 2 mcg/ml

(PONV 01-MIPS 430) Measure Specification Page 7 of 10 PONV Risk Factor- Intended Administration of Opioids for Postop Analgesia MPOG Concept IDs: 10642 Bupivacaine w/ Fentanyl 0.01% / 4 mcg/ml 10643 Bupivacaine w/ Fentanyl 0.25% / 4 mcg/ml 10644 Bupivacaine w/ Fentanyl 0.25% / 2 mcg/ml 10646 Bupivacaine w/ Hydromorphone 0.125% / 20 mcg/ml 10648 Bupivacaine w/ Hydromorphone 0.1% / 20 mcg/ml 10654 Bupivacaine w/ Fentanyl 0.167% / 16.67 mcg/ml 10669 Bupivacaine w/ Fentanyl 0.25% / 10 mcg/ml 11120 Bupivacaine w/ Fentanyl 0.05% / 5 mcg/ml 11130 Bupivacaine w/ Fentanyl 0.25% / 2.5 mcg/ml 11140 Bupivacaine w/ Fentanyl 0.05% / 2 mcg/ml Data Diagnostics Affected: Percentage of Cases with Professional Fee Procedure Codes Percentage of Cases with Antiemetic Medications Percentage of Cases in which the Patient has a known Gender Percentage of Intraoperative tes with a Meaningful te Mapping Percentage of Preoperative tes with a Meaningful Type Mapping Collations Used: History of PONV History of Motion Sickness Tobacco Smoking Classification

(PONV 01-MIPS 430) Measure Specification Page 8 of 10 Case Viewer Template: Other Measure Build Details: If smoking status is not documented, patient is assumed to be a non-smoker and therefore is assigned at least one risk factor. Success: Patient receives combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively or intraoperatively Anti-emetic therapy: The recommended first- and second-line classes of pharmacologic antiemetics for PONV prophylaxis in patients at moderate to severe risk of PONV include (but are not limited to): NK-1 Receptor Antagonists 5-Hydroxytryptamine (5-HT3) Receptor Antagonists Glucocorticoids Phenothiazines Phenylethylamines Butyrophenones Antihistamines Anticholinergics te: The foregoing list of medications/drug names is based on clinical guidelines and other evidence. The specified drugs were selected based on the strength of evidence for their clinical effectiveness. This list of selected drugs may not be current. Physicians and other health care

(PONV 01-MIPS 430) Measure Specification Page 9 of 10 professionals should refer to the FDA s web site page entitled Drug Safety Communications for up-to-date drug recall and alert information when prescribing medications. Threshold: 90%. Responsible Provider: Provider(s) signed in at Induction End. Method for determining Responsible Provider: 1. Provider signed in at Anesthesia Induction End. If not available then, 2. Provider signed in at Anesthesia Induction Begin. If not available then, 3. Provider signed in at Procedure Start. If not available then, 4. Provider signed in at Patient in Room. If not available then, 5. Provider signed in Anesthesia Start. Risk Adjustment (for outcome measures): t applicable. References: 1. Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesthesia and analgesia. 2014;118(1):85-113. 2. White PF, Kehlet H, Neal JM, Schricker T, Carr DB, Carli F. The role of the anesthesiologist in fasttrack surgery: from multimodal analgesia to perioperative medical care. Anesthesia and analgesia. 2007;104(6):1380-1396, table of contents.

(PONV 01-MIPS 430) Measure Specification Page 10 of 10 PONV 01 Flow Diagram Start: All Patients Patient Age 18 years old? Exclude Appropriate Case by CPT Inclusion List* Exclude *Refer to Page 2 of this measure specification for the complete list of included procedures by CPT code. Received Inhalational Anesthetic Agent Exclude **PONV Risk Factors: 1) Female? 2) n-smoker? (If smoking documentation is not present, assume patient is non-smoker.) 3) Intended administration of opioids for Patient exhibits 3 risk factors** for PONV? Exclude postoperative analgesia. This includes use of opioids given intraoperatively. 4) Documented history of PONV? 5) Documented history of Motion Sickness? Receiv ed at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively or intraoperatively? Medical Reason documented for not receiving at least 2 prophylactic pharmacologic anti-emetic agents (MPOG Concept ID: 50046) Exclude Pass Fail